Affiliate disclosure
Book titles on this page link to Amazon. As an Amazon Associate, DataField.Dev earns from qualifying purchases — at no additional cost to you.
Chapter 27 — Further Reading
⚠️ This is the fastest-moving area in the book. Anything I write here will date sooner than the rest, which is itself a reason to read primary sources rather than summaries — including this one.
⚠️ The four papers that carry the chapter
Wastyk HC et al., "Gut-microbiota-targeted diets modulate human immune status," Cell, 2021. Search "fermented food fibre diet immune status Stanford trial."
⚠️ This is §27.9 and the fermented-food verdict. Read the sample size and duration before the results, then read the results, then read the discussion — where the authors are careful about what a ten-week diversity outcome does and doesn't say about fibre.
Suez J, Zmora N et al., the two 2018 Cell papers — search "probiotics mucosal colonization resistance personalized" and "probiotics delay gut microbiome reconstitution after antibiotics."
⚠️ These are §27.7, and they are the most counterintuitive findings in the chapter. Small, mechanistic, and they invert the standard recommendation. Read them knowing they are mechanistic studies rather than outcome trials — which is exactly how I've weighted them.
Sender R, Fuchs S, Milo R (2016) — search "revised estimates bacteria human cells ratio." ⚠️ Short, and it is a small masterpiece of checking a number everyone had repeated.
And the paediatric gastroenteritis trials — search "probiotic acute gastroenteritis children randomized trial 2018 New England Journal." ⚠️ Two of them, published together. Read them as a case study in how a field updates.
On what sequencing can and can't do
Search "16S rRNA versus shotgun metagenomics comparison limitations" for the methodological contrast, and ⚠️ "microbiome study reproducibility DNA extraction bias" for §27.3b's material.
⚠️ If you want to understand why two labs disagree, read one paper on extraction-method bias. It will do more for your scepticism about consumer reports than any critique of the industry.
On consumer testing specifically: search "direct-to-consumer microbiome testing validity" and "microbiome test clinical utility position statement." ⚠️ Several professional bodies have issued statements and they are notably blunt.
On SCFAs and fibre
Search "short-chain fatty acids butyrate colonocyte energy" for the mechanism, and "SCFA GLP-1 PYY appetite regulation" for the link to Chapters 3 and 24.
⚠️ Then reread Chapter 11's further reading. The convergence in §27.4 is the point, and seeing the same recommendation arrive from cardiovascular epidemiology, glycaemic control, colorectal cancer and microbial ecology is more persuasive than any single source.
On resistant starch: search "resistant starch types fermentation butyrate." ⚠️ Cooling cooked potato, rice and pasta increases it, which is a free and slightly surprising intervention.
On probiotics — read a guideline, not a review
The World Gastroenterology Organisation global guidelines on probiotics and prebiotics — ⚠️ free, organized BY INDICATION AND BY STRAIN, which is exactly the structure §27.6 argues for.
Also useful: your national gastroenterology society's position, and ⚠️ the ISAPP consensus statements (International Scientific Association for Probiotics and Prebiotics) on the definitions of probiotic, prebiotic, synbiotic and fermented food — which are clearer than the marketing and free.
⚠️ And on the neonatal safety issue: search "FDA warning probiotics preterm infants 2023." Read it if you are anywhere near this decision.
On FMT
Search "faecal microbiota transplantation recurrent Clostridioides difficile randomized trial" for the efficacy evidence, and ⚠️ "FDA safety alert fecal microbiota transplantation multidrug-resistant organism 2019" for why donor screening exists.
⚠️ If you are considering DIY FMT, read the second one first. It describes a death.
On the wider indications: search "FMT ulcerative colitis randomized" and "FMT irritable bowel syndrome trials." ⚠️ Note how the effect sizes shrink as you move away from C. difficile, and consider why.
⚠️ On IBS and low-FODMAP — the practical section
Monash University's FODMAP resources (monashfodmap.com) — ⚠️ the group that developed the
framework. Their app and educational material describe all three phases, and the reintroduction
material is what most people never reach.
Your national IBS guideline — NICE in the UK, and equivalent bodies elsewhere. ⚠️ Read the first-line dietary advice section, because it should usually come before low-FODMAP and frequently doesn't.
On the gut–brain treatments: search "gut-directed hypnotherapy irritable bowel syndrome randomized" and "cognitive behavioural therapy IBS trial." ⚠️ The effect sizes are comparable to dietary intervention and provision is far lower — which is a service problem, not an evidence problem.
On peppermint oil: search "peppermint oil IBS meta-analysis."
⚠️ And if you are currently restricting: the single most useful thing on this page is Monash's reintroduction protocol. Case Study 2 is what happens without it.
On the other conditions
Exclusive enteral nutrition: search "exclusive enteral nutrition paediatric Crohn's disease induction remission." ⚠️ This surprises most people, including many adults with IBD, and it is well established.
Diverticular disease: search "nuts seeds popcorn diverticular disease prospective cohort." ⚠️ The study that overturned decades of advice. Chapter 17's stale-guidance category.
"Leaky gut": search "intestinal permeability measurement clinical significance review." ⚠️ Read something written by gastroenterologists rather than by anyone selling a protocol — the physiology is genuinely interesting and the syndrome is not a diagnosis.
A note on what to be careful with
⚠️ This chapter has an unusual failure mode: it is the one most likely to make a reader cynical about a field that is genuinely producing good science.
Three things I'd want protected:
1. ⚠️ The mechanisms are real. SCFAs, colonization resistance, immune education, drug metabolism — none of that is marketing. Chapter 19 §19.11's warning applies at full strength: dismissing the products should not make you dismiss the biology.
2. ⚠️ FMT genuinely cures a disease. That is not a small thing, and it demonstrates that community manipulation can be therapeutic when the problem is the right shape.
3. And the field is young. ⚠️ Twenty years is not long, the tools have improved enormously, and "the clinical yield so far is modest" is a description of the present, not a prediction.
⚠️ The symmetric warning, for the enthusiastic reader:
If you finish this chapter still thinking a microbiome test will tell you what to eat, ⚠️ do the exercise in Case Study 1's Your Turn — look for a published reference range, a described comparison population, a citation to a trial, and a statement of reproducibility. Four things. They should all be there and in my experience none of them are.
And the two things I'd most want retained:
⚠️ Probiotic effects are strain-specific, and almost nothing on a shelf names a strain and an indication.
⚠️ Low-FODMAP is a diagnostic process with three phases, and doing the first one indefinitely is not a milder version of doing it properly — it is a different and worse intervention.